FDA Approves Inavolisib Breast Cancer Treatment

By Rene Pretorius

October 15, 2024

The FDA's approval of inavolisib breast cancer treatment in combination with palbociclib and fulvestrant is significant. It provides a new treatment option for a challenging patient population. This treatment is specifically for adults with endocr...

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.